Sleep physiology features from wearable trackers predict next-day physical fatigue in healthy adults with moderate discriminative capacity
The study evaluated the feasibility of using consumer- and research-grade sleep trackers to predict next-day fatigue and sleepiness in individuals with neurodegenerative and immune-mediated inflammatory diseases. In healthy adults, machine learning models achieved an AUC of 0.75 for predicting next-day physical fatigue, with respiratory rate and REM sleep duration as key features. Predictive performance was lower in chronic disease cohorts (AUC 0.62 for physical fatigue in NDD).
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Sleep physiology features from wearable trackers predict next-day physical fatigue in healthy adults with moderate discriminative capacity The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
Sleep physiology features from wearable trackers predict next-day physical fatigue in healthy adults with moderate discriminative capacity
This conclusion is most relevant to: 134 participants (42 healthy adults, 39 with neurodegenerative diseases, 53 with immune-mediated inflammatory diseases) across four European centres.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Exploring the feasibility of modeling next-day fatigue and sleepiness using digital sleep tracker data in neurodegenerative and immune-mediated inflammatory diseases. (Frontiers in digital health, 2026) —
How It Works
The proposed biological pathway:
- ▸Wearable sleep trackers capture physiological and sleep-architecture features (e.g., respiratory rate, REM sleep duration, REM latency, deep sleep)
- ▸Machine learning models are trained on these features to predict next-day fatigue and sleepiness
- ▸Models are evaluated using leave-one-subject-out cross-validation
- ▸Result: Preliminary discriminative capacity for next-day physical fatigue, particularly in healthy adults
Who Might Benefit
Evidence fit by population:
- ▸134 participants (42 healthy adults, 39 with neurodegenerative diseases, 53 with immune-mediated inflammatory diseases) across four European centres
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Outcome binarisation using a global threshold may conflate between-person disease-group differences with within-person symptom variation
- ▸Predictive performance in chronic disease cohorts remains limited, underscoring the need for larger, multimodal studies
- ▸Findings are exploratory and not confirmatory
Frequently Asked Questions
What sleep features were most predictive of next-day fatigue?▼
Respiratory rate and REM sleep duration were the key drivers for predicting physical fatigue in healthy adults. In neurodegenerative disease, REM latency and deep sleep were important features.
How accurate were the sleep trackers compared to polysomnography?▼
The sleep trackers showed moderate agreement with polysomnography in a sub-study of 28 participants.
Can these findings be applied to people with chronic diseases?▼
Predictive performance was limited in neurodegenerative and immune-mediated inflammatory disease cohorts (AUC ≤ 0.66), so the findings are not yet clinically applicable to these populations.
What is the main limitation of this study?▼
The binarisation of fatigue outcomes using a global threshold may mix between-person differences with within-person variation, and the study is exploratory without definitive clinical recommendations.
References
- 1.Zhai B, Chen L, Ma X, Pinaud C, Chatterjee M, Kortelainen JM, Rehman RZU, Ahmaniemi T, Avey S, Guan Y, Macrae V, Hinchliffe C, Del Din S, Manyakov NV, Göder R, Romijnders R, Maetzler W, Reilmann R, Aufenberg S, Schubert R, van der Woude CJ, Zhang D, Ng WF. “Exploring the feasibility of modeling next-day fatigue and sleepiness using digital sleep tracker data in neurodegenerative and immune-mediated inflammatory diseases..” Frontiers in digital health, 2026. PMID: 42388291 DOI: 10.3389/fdgth.2026.1752629